Welcome to our dedicated page for Aquestive Therapeutics SEC filings (Ticker: AQST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aquestive Therapeutics, Inc. filings document the regulatory, financial, governance, and capital-structure disclosures of a specialty pharmaceutical company built around oral-film drug delivery, proprietary product candidates, and CDMO/licensee manufacturing. Its 8-K reports include FDA communications and Regulation FD materials for Anaphylm™, financial results, investor presentations, and material agreements related to revenue-sharing, warrants, and common-stock purchase commitments.
Proxy materials describe annual-meeting voting matters, director elections, executive compensation, auditor ratification, and board governance. Other current reports record officer-transition matters, compensatory arrangements, exhibits, and product-development updates tied to the company’s regulatory strategy.
Aquestive Therapeutics, Inc. (AQST) reported that Chief Commercial Officer Sherry Korczynski exercised stock options and sold shares on September 9, 2026. She exercised 8,750 non-qualified stock options at an exercise price of $2.65 per share, converting them into 8,750 shares of common stock, and then sold 8,750 common shares at $5.22 per share. Following the option exercise, she held 26,250 stock options directly, with the exercised option series expiring on March 7, 2035. The sales were made pursuant to a previously adopted Rule 10b5-1 Trading Plan, indicating they were pre-arranged.
Aquestive Therapeutics, Inc. (AQST) reported that Chief People Officer Peter E. Boyd exercised a Common Stock Purchase Warrant on September 9, 2026 to acquire 2,293 shares of common stock at an exercise price of $0.96 per share, a cash exercise of a warrant issued in June 2022. The corresponding warrant position of 2,293 warrant rights was fully exercised, leaving no remaining warrants from this grant, and Boyd now holds 284,024 shares of Aquestive common stock directly. No Rule 10b5-1 trading plan is reported for these transactions.
Aquestive Therapeutics, Inc. (AQST) reported that President and CEO Daniel Barber exercised a Common Stock Purchase Warrant for 91,743 shares of common stock on September 8, 2026 at an exercise price of $0.96 per share for cash, increasing his direct common stock holdings to 677,317 shares and exhausting the warrant.
Aquestive Therapeutics, Inc. (AQST) is the issuer for a planned resale of its common stock reported under Rule 144 by officer Sherry M. Korczynski. The notice covers up to 8,750 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC, arising from an exercise of stock options for cash, with an approximate aggregate market value of $45,587.50, and a stated sale date of September 9, 2026 on NASDAQ.
Aquestive Therapeutics, Inc. (AQST) reported that Chief Operating Officer Cassie Jung exercised a warrant to acquire 4,587 shares of Common Stock on September 3, 2026 by paying an exercise price of $0.96 per share, in a transaction not reported as made under a Rule 10b5-1 plan.
The related warrant, originally issued on June 8, 2022 under a Securities Purchase Agreement dated June 6, 2022, became exercisable on December 8, 2022 and expires on June 8, 2027, and now reflects 0 warrants remaining after the exercise. Following this transaction, Jung holds 206,833 shares of Common Stock directly and 2,000 shares indirectly through her spouse.
Aquestive Therapeutics, Inc. (AQST) reported that its President and CEO, Daniel Barber, sold common stock pursuant to a Rule 10b5-1 trading plan. On 2026-08-17, he sold 25,000 shares of common stock in open market or private transactions at a weighted average price of $4.2867 per share, with individual sale prices ranging from $4.24 to $4.35 per share. Following this transaction, Barber directly holds 585,574 shares of Aquestive Therapeutics common stock.
Aquestive Therapeutics, Inc. executive Sherry Korczynski, Chief Commercial Officer, reported a Form 4 transaction involving company common stock. On 2026-08-14, 2,714 shares of common stock were withheld by the issuer at $4.25 per share to satisfy her tax withholding obligation arising from the vesting of previously granted Restricted Stock Units (RSUs). After this tax-withholding disposition, she directly holds 235,689 shares of Aquestive Therapeutics common stock.
Aquestive Therapeutics insider Daniel R. Barber filed a notice of proposed sales of 25,000 shares of common stock of AQST, with an aggregate market value of $106,250.00, expected on August 17, 2026. The shares relate to Restricted Stock Units originally dated March 9, 2026. The filing also lists prior 10b5-1 plan sales of AQST common stock during the past three months.
Aquestive Therapeutics reported higher revenues but continued losses for the quarter and six months ended June 30, 2026. Quarterly revenue rose to $13,819 from $10,003, and six‑month revenue increased to $28,265 from $18,723, driven largely by manufacture and supply and higher license and royalty revenue, including $5,000 of Zevra‑related royalties.
Loss from operations narrowed to $8,223 from $11,368 for the quarter and to $12,427 from $30,733 for the six months, but a $11,683 loss on extinguishment of debt associated with refinancing 13.5% notes with a new Oaktree $55,000 Term Loan Facility increased quarterly net loss to $22,864. Six‑month net loss improved to $30,921 from $36,478.
Cash and cash equivalents were $98,490 at June 30, 2026, down from $121,169 after $24,247 of operating cash use and debt retirement costs, partly offset by equity raised through the ATM facility and new debt proceeds. Total liabilities exceeded assets, resulting in a stockholders’ deficit of $56,586, and the company carried $51,886 of royalty obligations linked to future Anaphylm and Libervant sales. Management states that existing cash, expense management, and capital markets access provide liquidity for at least the next twelve months.
Aquestive Therapeutics reported second quarter 2026 results with total revenues of $13.8 million, up from $10.0 million a year earlier, driven mainly by higher manufacture and supply revenue and increased license and royalty revenue. Manufacture and supply revenue rose to $11.9 million, while royalty-based products, including Sympazan, contributed to growth as manufacturing volumes increased to about 48 million doses from 37 million in the prior-year quarter.
GAAP performance weakened as the company recorded a net loss of $22.9 million versus $13.5 million last year, largely due to a $11.7 million one-time loss on extinguishment of 13.5% notes and higher selling, general and administrative expenses. However, non-GAAP adjusted EBITDA loss improved to $5.2 million from $9.3 million. Cash and cash equivalents were $98.5 million as of June 30, 2026, though the balance sheet showed a stockholders’ deficit of $56.6 million alongside substantial debt and royalty obligations.
Strategically, Aquestive completed the human factors and pharmacokinetic studies needed to address the FDA Complete Response Letter for Anaphylm and reaffirmed plans to resubmit the NDA in Q3 2026, seek ex‑U.S. approvals starting in late 2026, and continue advancing its AdrenaVerse™ epinephrine platform, including AQST‑108 for dermatologic indications. The company maintained its 2026 guidance for total revenue of $46–$50 million and non‑GAAP adjusted EBITDA loss of $35–$30 million.